RA0274

antibody from Oursmab

Targeting: GIPR

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0274

Provider

Oursmab

Product name

Maridebart (Biosimilar Reference Antibody) (GIPR)

Antibody type

Monoclonal

Description

Maridebart (AMG 133) is an investigational antibody-peptide conjugate designed for the treatment of obesity and type 2 diabetes. Its unique structure consists of a monoclonal antibody scaffold conjugated to engineered peptide modules that confer dual agonism/antagonism: it acts as a glucagon-like peptide-1 (GLP-1) receptor agonist and a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist. This dual mechanism aims to amplify GLP-1-mediated appetite suppression and glycemic control while simultaneously blocking GIP signaling, which is hypothesized to further enhance weight loss. By leveraging the long half-life of an antibody format, it is developed as a once-monthly subcutaneous injection to improve patient adherence.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.